US FDA Authorizes Risk Modification Claim for Zyn Nicotine Pouch Products

The U.S. Food and Drug Administration (FDA) has authorized a risk modification claim for 20 Zyn nicotine pouch products, allowing the manufacturer to state that using these products instead of cigarettes reduces the risk of several serious health conditions. According to an FDA press release, the authorized claim specifies that using Zyn instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.

The authorization applies to products that were previously approved for sale in the U.S. in 2025. This regulatory move allows the company to market the pouches as a lower-risk alternative to combustible tobacco products.

Which Zyn products can use the risk modification claim?

The FDA’s authorization covers 20 specific product variations. These include 10 distinct flavors, each available in two different nicotine strengths: 3 mg and 6 mg. According to the FDA, the authorized flavors are:

• Chill
• Cinnamon
• Citrus
• Coffee
• Cool Mint
• Menthol
• Peppermint
• Smooth
• Spearmint
• Wintergreen

What health risks are reduced compared to cigarettes?

The FDA-authorized claim focuses on the reduction of risks associated with the inhalation of combustible tobacco. The agency permits the manufacturer to state that Zyn pouches lower the risk of the following conditions when used as a replacement for cigarettes:

• Lung cancer and mouth cancer
• Heart disease and stroke
• Emphysema and chronic bronchitis

This modification claim is distinct from a “risk-free” claim. It specifically positions the product as a modification of risk relative to the use of cigarettes, rather than asserting that the nicotine pouches are harmless.